Hematopoietic stem cells (HSCs) are the foundation of the body's blood cell production, primarily located in the bone marrow. These extraordinary cells can self-renew and differentiate into all blood cell types.¹

As the driving force of hematopoiesis, HSCs ensure the constant renewal of blood cells essential for oxygen delivery, immune protection, and clotting. Their adaptability and regenerative capacity have positioned them at the forefront of medical research, unlocking transformative potential for treating blood disorders, cancers, and immune-related conditions through stem cell therapies and bone marrow transplants.

Hematopoiesis

Hematopoiesis is the process by which the body produces blood cells, including red blood cells, white blood cells, and platelets.² It occurs primarily in the bone marrow, where hematopoietic stem cells divide and differentiate into various blood cell types. This continuous process ensures the body maintains adequate levels of blood cells for functions like oxygen transport, immune response, and clotting. Hematopoiesis is tightly regulated by growth factors and cytokines to meet physiological demands.

Hematopoietic stem cells continuously replenish the body's supply of red blood cells (for oxygen transport), white blood cells (to support immune defense), and platelets (for blood clotting and wound repair). HSCs ensure a steady reservoir of cells capable of differentiating into various blood cell types essential for physiological balance.

Unique properties of hematopoietic stem cells

HSCs undergo asymmetrical division to produce two daughter cells. One daughter cell can self-renew, and that allows them to maintain the population of the stem cells². The other daughter cell is the progenitor cell, destined for proliferation and differentiation into multiple blood cell types². This multipotent nature of the progenitor cells helps to constantly generate specialized cells that have specific functions in the hematopoietic system.

Self-renewal and differentiation: One of the most fundamental properties of hematopoietic stem cells is their ability to self-renew³. This allows them to divide and create similar stem cells for long-term function, as well as ensuring that the blood system is replenished throughout one's life.

Multipotency and lineage commitment: Hematopoietic stem cells are considered multipotent since they can differentiate into a variety of cell types. One of the two daughter cells formed from HSC that proliferate and differentiate into more lineage-restricted blood cells is called multipotent progenitors (MPP). The multipotent progenitors then differentiate into lineage-committed progenitors, which eventually give rise to specific blood cell types. The MPPs do not have self-renewal capability⁴.

The ability of the HSCs to self-renew and differentiate is controlled by sophisticated transcription factors, which are proteins that regulate gene expression, and signaling molecules, such as growth factors and cytokines, that regulate multilineage differentiation. Concerted regulation of the transcription factors ensures that the body generates the necessary amount of blood cell types to maintain physiological functions, fight an infection, or heal from an injury.

Quiescence and activation: Another property of the hematopoietic stem cells is their ability to enter a quiescent or dormant state³. This is a dormancy in which stem cells can remain alive for long periods. HSCs do not actively divide but instead spend most of their time in reserve, ready to re-enter the cell cycle in the presence of signaling cues.

Under stressful conditions, such as blood loss or infection, latent HSCs can become activated, multiplying, and differentiating into the many blood cells required. In other words, activation allows the body to effectively adapt to possible physiological stimuli while keeping the HSC pool active. Quiescence is a fundamental property of HSCs in adult bone marrow, protecting them from functional exhaustion and ensuring lifelong blood cell production.

Trans-differentiation: This property of HSCs is referred to as the irreversible conversion of one differentiated cell type into another¹. HSCs have been reported to transdifferentiate into a wide range of cell types, including endothelial cells, skeletal muscle fibers, cardiomyocytes, and even neurons. Trans-differentiation across germ layers, such as mesoderm-derived HSCs generating ectoderm-derived neural cells, illustrates the exceptional plasticity of these cells¹.

Locations of hematopoietic stem cells

During embryonic development, hematopoietic stem cells first appear in the aorta-gonad-mesonephros (AGM) area, yolk sac, placenta, and umbilical arteries. The AGM region plays a vital role as it is the first site where definitive HSCs are generated. This region is capable of long-term multilineage reconstitution^1. Hematopoiesis in the yolk sac is termed primitive hematopoiesis, and is necessary for early embryonic survival^5,6.

Later, hematopoiesis shifts to the fetal liver, which becomes the major hematopoietic organ during mid-gestation. The placenta has also been recognized as an important, transient hematopoietic organ, contributing significantly to the expansion of HSCs during development^5,6.

In adults, they are typically found in the bone marrow but can be mobilized to the peripheral blood under certain situations. The adult bone marrow provides a highly specialized microenvironment, known as the hematopoietic niche, that supports HSC maintenance, quiescence, and differentiation.

The bone marrow's structural organization is compartmentalized into vascular niches and endosteal niches⁷. The vascular niche, composed primarily of sinusoidal endothelial cells, maintains HSCs in a proliferative, activated state, whereas the endosteal niche, near the bone surface, promotes HSC quiescence. This spatial organization is important for balancing stem cell self-renewal with differentiation, ensuring the lifelong supply of blood cells.

Furthermore, mesenchymal stromal cells and osteoblastic cells within the endosteal niche produce pivotal retention factors such as CXCL12 and angiopoietin-1, helping anchor HSCs within specific marrow regions⁸.

Embryonic origins: Hematopoietic stem cells originate in the AGM region, where they first emerge during embryonic development⁸. This region is critical for the initiation of hematopoiesis and serves as a key focus for studying the early formation and evolution of the blood system.

Endothelial-to-hematopoietic transition (EHT), a unique process in the AGM, plays a pivotal role in the emergence of the first definitive HSCs¹. Studies using animal models have shown that mutations impairing the AGM region can severely affect lifelong hematopoiesis, underlining its importance.

Aside from the AGM, the yolk sac, placenta, and umbilical arteries are also producers. These sites play an essential role in the early stages of hematopoiesis before the bone marrow takes over as the principal site of HSC generation.

Yolk sac-derived blood islands produce primitive erythrocytes and macrophages, while placental hematopoiesis appears to be vital in amplifying the HSC pool before they colonize the fetal liver and, eventually, the bone marrow.

Interestingly, recent evidence suggests that the placenta might serve as a protected reservoir, shielding nascent HSCs from inflammatory signals that could otherwise impact their development.

Adult locations: In adults, a significant proportion of hematopoietic stem cells are found in bone marrow, specifically in the trabecular gaps of the femur, tibia, and other long bones⁷. HSCs are also abundant in flat bones such as the pelvis, sternum, and vertebrae, which are preferred sites for bone marrow aspiration and biopsy¹⁰.

The bone marrow microenvironment, known as the hematopoietic niche, creates ideal circumstances for HSCs to function and multiply. It promotes stem cell self-renewal and differentiation by interacting with several other cell types, including stromal and endothelial cells, as well as signaling molecules that control stem cell behavior. Stromal cells secrete essential cytokines such as stem cell factor (SCF), thrombopoietin (TPO), and CXCL12, which are essential for HSC retention and survival within the niche^6,7.

Under certain conditions, such as injury or disease (stress), hematopoietic stem cells may develop in the peripheral blood, albeit in very modest numbers. This is known as mobilization and can be pharmacologically enhanced using agents such as granulocyte colony-stimulating factor (G-CSF) and CXCR4antagonists like plerixafor to facilitate HSC collection for transplantation¹⁰.

Mobilized peripheral blood HSCs are one of the common sources of stem cells used in autologous and allogeneic transplants, offering faster engraftment times compared to bone marrow-derived HSCs. Additionally, inflammatory cytokines such as IL-1β and TNF-α have been shown to influence HSC egress into circulation under stress conditions¹¹.

Umbilical cord blood is another source of HSCs that is abundant and highly effective for transplantation therapy. These are harvested from the placenta after birth and have lately gained popularity as an alternate source for bone marrow transplants, primarily in pediatric patients. Cord blood HSCs are less mature immunologically, reducing the risk of graft-versus-host disease (GVHD) and enabling transplantation across greater human leukocyte antigen (HLA) mismatches¹⁰.

The hematopoietic niche

The hematopoietic niche is a microenvironment that coordinates the activity of stem cells. The niche consists of supportive stromal cells, adhesion molecules, extracellular matrix components, and signaling molecules that aid in HSC survival, renewal, proliferation, and differentiation^6,8. The interactions between hematopoietic stem cells and niche components are vital for maintaining a balance of quiescence and activation and ensuring that blood cell output satisfies the requirements of the body. Any disruption in this niche can lead to hematopoietic abnormalities, including malignancies like leukemia¹²​.

Bone marrow microenvironment: HSCs thrive in the bone marrow milieu, interacting with stromal cells such as osteoblasts, endothelial cells, and macrophages. Within this niche, the endosteal region near the trabecular bone is thought to be historically important, where HSCs are found in close proximity to osteoblasts and vasculature¹³.

The microenvironment supports self-renewal and differentiation of hematopoietic stem cells into numerous blood cell types. The distinct cellular architecture and signaling pathways in bone marrow play a vital role in maintaining the balance between stem cell quiescence and activity.

For example, the chemokine stromal-derived factor 1 (SDF1, also known as CXCL12), produced by stromal cells, plays an essential role in anchoring HSCs within the marrow and regulating their quiescence¹⁴​. Furthermore, real-time imaging studies have demonstrated that HSCs localize near both the endosteal surface and the vascular sinuses, suggesting the existence of potentially overlapping endosteal and perivascular niches.

Stromal cells and their influence on HSCs: Stromal cells in the bone marrow niche are important for regulating hematopoietic stem cells. They provide physical support and secrete cytokines, growth factors (like stem cell factor (SCF), granulocyte colony-stimulating factor (G-CSF), and interleukin-6 (IL-6)) and extracellular matrix proteins that influence stem cell behavior¹⁴.

In addition to soluble factors, adhesion molecules like N-cadherin and integrins mediate direct cell-to-cell contact, reinforcing HSC retention within the niche​. Although N-cadherin was initially implicated in niche adhesion, later studies revealed that N-cadherin-deficient mice showed no major defect in HSC maintenance, suggesting that redundant mechanisms exist to preserve niche integrity¹⁴​.

Disruption of HSC-stromal cell contact through chemical or other means can trigger premature differentiation and proliferation of HSCs.

Hematopoietic growth factors and regulatory signals: The activity of HSCs is also regulated by cytokines and hematopoietic growth factors. These chemicals are essential for coordinating HSC development into blood lineages and preserving the equilibrium of blood cell synthesis. Some of the common growth factors that modulate blood cell formation in response to physiological demand are erythropoietin (EPO), which promotes red blood cell production; granulocyte colony-stimulating factor (G-CSF), which stimulates granulocyte formation; and cytokine thrombopoietin (TPO), which supports platelet generation.

Besides these classical factors, niche-derived signals such as angiopoietin-1 (Ang1) interacting with the Tie2 receptor are crucial for maintaining HSC quiescence​. Disruption of these regulatory axes, for instance, through environmental insults or genetic mutations affecting stromal cell signaling, has been shown to disturb HSC homeostasis, leading either to exhaustion or uncontrolled proliferation¹⁴​.

Furthermore, pathways like Notch and Wnt signaling intricately regulate HSC behavior; Wnt3a, for example, promotes self-renewal, while Wnt5a influences HSCs by inhibiting canonical Wnt signaling, suggesting a complex regulatory network within the niche¹⁴​.

Again, BMP4/TGF-β pathways are important for niche development and stem cell regulation¹⁴. Disruptions of this can lead to HSC exhaustion or leukemic transformation​.

Niche dysregulation and hematopoietic abnormalities

The hematopoietic niche not only supports healthy blood formation but can also become a source of pathology when disrupted. Environmental toxins (such as benzene), radiation, or genetic mutations affecting niche components can disturb the HSC microenvironment, leading to diseases such as myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML).

Research has shown that dysfunction of the niche alone, without any intrinsic mutations in HSCs, can initiate myeloproliferative disease. For example, alterations in stromal Notch signaling or defects in cell cycle regulators such as Rb and Rarg within niche cells have been linked to dysregulated hematopoiesis¹⁴.

Furthermore, changes in the micro-environmental cytokine profile can bias hematopoietic differentiation toward specific lineages, potentially influencing the development and phenotype of hematological malignancies.

Understanding HSC differentiation

Hematopoietic stem cells differentiate into long-term (LT-HSCs) and short-term (ST-HSCs) progenitors¹⁵. LT-HSCs can self-renew indefinitely, ensuring lifelong blood production, while ST-HSCs contribute temporarily. During differentiation, HSCs give rise to multipotent progenitors, which gradually commit to specific blood lineages, producing red blood cells, white blood cells, or platelets.

Long-term vs. short-term HSCs: LT-HSCs are a population of quiescent cells residing in the bone marrow that can self-renew indefinitely, giving a lifetime supply of blood cells. Furthermore, these cells are required to maintain the creation of blood cells throughout an organism's existence.

LT-HSCs are characterized by low metabolic activity and a dormant state that protects them from exhaustion and environmental stress. Markers such as CD34⁻, CD90+^, and CD38⁻ are commonly used to identify human LT-HSCs¹⁶.

ST-HSCs are lineage-committed cells that depend on intrinsic and extrinsic cues to differentiate into lineage-specific cells. Unlike LT-HSCs, ST-HSCs possess a limited capacity for self-renewal and serve as an immediate but transient source of blood cells. ST-HSCs typically express markers such as CD34⁺ and CD38⁺, indicating a primed state for differentiation¹⁶.

Multipotent and lineage-committed progenitors: The short-term hematopoietic stem cells form hematopoietic progenitor cells, which further segregate into common myeloid progenitors (CMPs) and common lymphoid progenitors (CLPs).

Common myeloid progenitors (CMPs) differentiate into two distinct progenitor types: granulocyte-macrophage progenitors (GMPs) and megakaryocyte-erythrocyte progenitors (MEPs).

GMPs develop into granulocytes (such as neutrophils, eosinophils, and basophils), monocytes, and dendritic cells, while MEPs give rise to erythrocytes (red blood cells that transport oxygen) and megakaryocytes (large cells that produce platelets essential for blood clotting).

The CLPs, on the other hand, give rise to T, B, NK, and dendritic cells, forming the basis of the adaptive and innate immune systems.

Each branch of differentiation is tightly regulated by specific transcription factors; for example, GATA1 promotes erythroid and megakaryocyte lineage commitment, whereas PU.1 drives myeloid and lymphoid lineage commitment¹⁷.

Extrinsic and intrinsic factors, including transcription factors, growth regulators, cell cycle modulators, epigenetics, and environmental factors, influence dynamic cellular organization and function within the hematopoietic system.

For instance, intrinsic regulators like the transcription factors RUNX1and TAL1 are essential for early HSC specification and maintenance, while extrinsic cues such as cytokines (eg, IL-3, erythropoietin) and interactions with the bone marrow niche (including stromal cells and extracellular matrix components) help to direct lineage fate decisions.

Epigenetic modifications like DNA methylation and histone acetylation also play crucial roles by regulating gene expression without altering the DNA sequence, thus allowing HSCs to remain flexible yet responsive to differentiation signals¹⁴.

Environmental stressors, such as infection, hypoxia, and inflammation, can also shift HSC fate; for example, during infection, HSCs may be skewed toward myeloid lineage production to meet the increased demand for innate immune cells.

Clinical applications of hematopoietic stem cells

HSCs have significant clinical applications, such as hematopoietic cell transplantation (HCT), graft-versus-tumor (GVT) therapy, induction of immune tolerance and gene therapy. It became popular (particularly the bone marrow transplantation) for treating blood disorders like leukemia, lymphoma, and anemia. Autologous transplants use a patient's HSCs, while allogeneic transplants involve donor cells.

Additionally, HSCs show potential in regenerative medicine, especially in gene therapy for genetic blood disorders such as sickle cell disease and thalassemia. Modifying HSCs to correct genetic mutations before reintroducing them offers promising treatments for these inherited conditions, potentially providing long-term cures.

Hematopoietic cell transplantation (HCT)

HCT is currently employed across three primary clinical scenarios: the treatment of malignancies, restoration or modulation of a defective hematopoietic or immune system, and treatment of genetic diseases where defective gene expression can be overcome by transplanted hematopoietic cells.

Bone marrow transplantation: Bone marrow transplantation is one of the most widely used clinical applications for hematopoietic stem cells. There are two types of bone marrow transplantation based on the source of stem cells used in the process. These different varieties are autologous transplantation and allogeneic transplantation¹.

Autologous transplants use a patient's stem cells, while allogeneic transplants use donor stem cells from someone with a compatible immune system. While potentially curative, it requires precise matching to prevent problems like graft-versus-host disease.

Bone marrow transplants are effective treatments for leukemia, lymphoma, and other blood disorders. In this process, HSCs are transferred from a healthy donor to people who have damaged or diseased bone marrow to treat the ailment.

Peripheral blood stem cell transplantation: Peripheral blood stem cell transplantation has become increasingly common due to faster hematologic recovery times compared to bone marrow sources. Mobilization agents like G-CSF are used to stimulate the release of HSCs into the bloodstream, after which they are collected through leukapheresis¹. While this method results in quicker recovery, it also carries a higher risk of chronic GVHD.

Umbilical cord blood (UCB) transplantation: Umbilical cord blood is a promising alternative source of HSCs. It is easy to collect, carries no risk to the donor, and contains more primitive cells capable of tolerating greater HLA mismatches¹. However, cord blood transplants often experience delayed engraftment, which can prolong recovery. Strategies such as double cord blood transplants and ex vivo expansion are being developed to overcome these limitations.

Strategies to avoid immune rejection: Several approaches are employed to minimize immune rejection in HCT¹:

• Immunosuppressive therapy: Used to suppress host immune responses.
• HLA matching: Advances in molecular typing have improved donor-recipient matching.
• Somatic cell nuclear transfer (SCNT): This technique generates autologous embryonic stem cell lines, potentially providing perfectly matched grafts, though practical challenges remain.
• Induction of immune tolerance: Tolerogenic dendritic cells derived from stem cells can precondition the immune system to accept transplanted tissues as self.

Graft-versus-tumor (GVT) effect

In addition to replacing diseased hematopoietic systems, allogeneic HSC transplants exert a powerful graft-versus-tumor effect. Donor immune cells can recognize and destroy residual malignant cells, contributing significantly to the cure rates of hematologic cancers. This effect is also being explored for solid tumors, such as kidney, breast, and colorectal cancers, broadening the therapeutic reach of HCT¹.

Induction of tolerance in solid organ transplants

HSC transplantation is also used to induce immune tolerance in organ transplant recipients. Transplantation of donor-derived hematopoietic stem cells along with a solid organ, such as a kidney, can create a mixed immune system (chimerism) that promotes acceptance of the graft without lifelong immunosuppression¹.

Hematopoietic stem cells in gene therapy

HSCs are ideal vehicles for gene therapy because of their long-term engraftment and ability to repopulate the blood system. Gene therapy involves ex vivo modification of a patient's HSCs using viral or non-viral vectors to introduce corrective genes before reinfusion¹.

Viral vectors: Retroviral and lentiviral vectors are commonly used due to their ability to stably integrate therapeutic genes into the host genome. Successful clinical applications have been reported in conditions like severe combined immunodeficiency (SCID) and beta-thalassemia.

Non-viral vectors: Although less efficient currently, non-viral methods such as plasmid DNA and nanoparticles offer the advantage of lower immunogenicity and easier manufacturing. Improving their delivery efficiency remains an active area of research.

Gene therapy for genetic blood disorders, such as sickle cell disease and thalassemia, has shown promising results. By correcting the underlying mutation in autologous HSCs and reinfusing them, patients can achieve long-term, potentially curative outcomes.

HSC plasticity and regenerative medicine

Beyond traditional hematologic applications, adult HSCs exhibit surprising plasticity, contributing to non-hematopoietic tissues under certain conditions. This plasticity broadens the potential of HSCs in regenerative medicine¹.

The use of adult stem cells, such as HSCs, avoids ethical issues associated with embryonic stem cells and offers the dual advantage of minimizing immunological rejection and reducing the risk of tumorigenesis. Mechanisms of tissue repair involve both direct differentiation of circulating stem cells and activation of local stem or progenitor cells.

For instance, circulating HSCs have been implicated in the regeneration of cardiac tissue following myocardial infarction and in hepatic regeneration after liver injury. Moreover, HSCs' regenerative capabilities are increasingly being harnessed in tissue engineering and gene therapy approaches for complex diseases, including autoimmune disorders and degenerative conditions such as osteoarthritis.

Challenges of hematopoietic stem cell research and medicine

Despite the enormous potential of hematopoietic stem cell therapy, research and clinical applications of hematopoietic stem cells face several formidable obstacles²⁰. The challenge of growing HSCs ex vivo while preserving their vital characteristics, like self-renewal and multipotency, is one of the primary obstacles.

Traditional culture methods often lead to differentiation or exhaustion of HSCs, making it difficult to generate sufficient numbers of functional stem cells for therapeutic use. Recent advances in biomaterials, niche-mimicking scaffolds, and small molecule modulators show promise but have not yet fully overcome this hurdle.

Furthermore, immunological rejection is still a significant worry, especially with allogeneic transplants. The use of embryonic stem cells raises additional ethical questions, such as those pertaining to tissue sourcing and consent. For HSC therapies to advance and reach their full potential in regenerative medicine, several obstacles must be overcome.

Graft-versus-host disease: A major challenge in hematopoietic stem cell research is the difficulty of culturing HSCs outside the body while preserving their stem-cell properties. Additionally, immune rejection remains a significant concern in allogeneic transplants, as the recipient's immune system may identify and reject the transplanted stem cells.

Ethical issues: The use of hematopoietic stem cells, especially those derived from embryonic tissues, continues to raise ethical concerns. While sourcing stem cells from adult donors or umbilical cord blood is generally accepted, the use of embryonic stem cells remains controversial due to issues surrounding consent, the origin of the tissue, and potential long-term consequences.

FAQs

What is the main role of hematopoietic stem cells?

The primary function of hematopoietic stem cells (HSCs) is to create all types of blood cells throughout their lifespan. HSCs are in charge of the ongoing regeneration of red blood cells, white blood cells, and platelets. They accomplish this by self-renewing to maintain their population and differentiating into diverse progenitor cells that give rise to different blood cell lineages. This ensures that the body's hematopoietic system stays functional and capable of reacting to changing physiological demands.

Can hematopoietic stem cells be used in gene therapy?

Hematopoietic stem cells (HSCs) can be employed for gene therapy. In this method, HSCs are removed from a patient, genetically changed outside the body to fix specific mutations, and then returned to the patient. This is especially beneficial when treating inherited blood disorders like sickle cell anemia and thalassemia. By rectifying genetic flaws in HSCs, the patient's blood cells are supplied with healthy, genetically edited cells, perhaps leading to a long-term treatment for these inherited disorders. This approach has enormous promise for regenerative medicine and gene therapy.

What are the major differences in the development of hematopoietic stem cells between mice and humans?

Hematopoietic stem cells (HSCs) grow differently in mice and humans, especially in the timing and location of their emergence. During mouse embryogenesis, HSCs first appear in the aorta-gonad-mesonephros (AGM) area, then in the yolk sac and placenta. While the AGM is essential in humans, HSCs develop first in the yolk sac and then in the fetal liver before being transported to the bone marrow. In humans, hematopoietic stem cells (HSCs) undergo a prolonged developmental phase in the fetal liver, which impacts their maturation, while in mice, HSCs transition to the bone marrow at an earlier stage.

How are genetic markers used to identify hematopoietic stem cells in embryonic tissues?

Genetic markers are used to identify hematopoietic stem cells (HSCs) in embryonic tissues by targeting specific cell surface proteins and transcription factors that are expressed uniquely by HSCs during early development. These markers help distinguish HSCs from other hematopoietic and non-hematopoietic cells.

In mice, key markers include CD34, CD45, and Sca-1, which are frequently employed together to enhance and separate HSCs. CD34 and CD38 are commonly used markers in humans, with CD34 being especially useful for detecting HSCs in fetal liver and bone marrow. Furthermore, transcription factors such as Runx1 and Scl/Tal1 are employed to identify early HSCs during hematopoietic system development, distinguishing between progenitors and stem cells at different stages of differentiation.

References:

1. Mosaad Y.M. Hematopoietic stem cells: an overview. Transfusion and Apheresis Science. 51(3), (2014).
2. Chapman J., Zhang Y. Histology, hematopoiesis. (2018).
3. Ng A.P., Alexander W.S. Hematopoietic stem cells: past, present and future. Cell Death Discovery. 3(1), (2017).
4. Seita J., Weissman I.L. Hematopoietic stem cell: self‐renewal versus differentiation. Wiley Interdisciplinary Reviews: Systems Biology and Medicine. 2(6), (2010).
5. Mikkola, H. K., Orkin, S. H. (2006). The journey of developing hematopoietic stem cells. Development (Cambridge, England), 133(19), 3733–3744, (2006).
6. Morrison S.J., Scadden D.T. The bone marrow niche for hematopoietic stem cells. Nature. 505(7483), (2014).
7. Lucas D. Structural organization of the bone marrow and its role in hematopoiesis. Current Opinion in Hematology. 28(1), (2021).
8. Pinho S., Frenette P.S. Hematopoietic stem cell activity and interactions with the niche. Nature Reviews Molecular Cell Biology. 20(5), (2019).
9. de Bruijn M.F., Speck N.A., Peeters M.C., et al. Definitive hematopoietic stem cells first develop within the major arterial regions of the mouse embryo. The EMBO Journal. 19(11), (2000).
10. Khaddour K., Hana C.K., Mewawalla P. Hematopoietic stem cell transplantation.In StatPearls. (2023).
11. Bowers E., Singer K. Obesity-induced inflammation: The impact of the hematopoietic stem cell niche. JCI Insight. 6(3), (2021).
12. Greim H., Kaden D.A., Larson R.A., et al. The bone marrow niche, stem cells, and leukemia: impact of drugs, chemicals, and the environment. Annals of the New York Academy of Sciences. 1310(1), (2014).
13. Crane G.M., Jeffery E., Morrison S.J. Adult hematopoietic stem cell niches. Nature Reviews Immunology. 17(9), (2017).
14. Renström J., Kröger M., Peschel C., et al. How the niche regulates hematopoietic stem cells. Chemico-Biological Interactions. 184(1–2), (2010).
15. Cheng H., Zheng Z., Cheng T. New paradigms on hematopoietic stem cell differentiation. Protein & Cell. 11(1), (2020).
16. Mann Z., Sengar M., Verma Y.K., et al. Hematopoietic stem cell factors: their functional role in self-renewal and clinical aspects. Frontiers in Cell and Developmental Biology. 10, (2022).
17. Orkin S.H., Zon L.I. Hematopoiesis: an evolving paradigm for stem cell biology. Cell. 132(4), (2008).
18. Cabezas-Wallscheid N., Klimmeck D., Hansson J., et al. Identification of regulatory networks in HSCs and their immediate progeny via integrated proteome, transcriptome, and DNA methylome analysis. Cell Stem Cell. 15(4), (2014).
19. Skulimowska I., Sosniak J., Gonka M., et al. The biology of hematopoietic stem cells and its clinical implications. The FEBS Journal. 289(24), (2022).
20. Ikehara S. Grand challenges in stem cell treatments. Frontiers in Cell and Developmental Biology. 1, (2013).